Immunic, inc. (VTL)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Cash flows from operating activities:
Net loss

-8,487

-7,691

-8,215

-14,714

-4,313

-4,812

-1,797

9,455

-14,388

-14,588

-12,481

-12,407

-12,602

-11,734

-10,178

-9,468

-9,589

-9,859

-12,300

-15,106

-14,758

-13,955

-12,797

-10,167

-10,748

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,144

-9,358

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

14

12

9

24

5

5

3

-217

224

218

216

229

335

404

420

490

494

381

325

328

294

234

310

246

297

231

231

174

163

Other

-

-

-

-

-

-

-

-

-4

-

0

5

-2

-

-1

1

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Revaluation of preferred stock warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Revaluation of future purchase rights liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,472

1,128

14

2,192

922

-4,434

Stock-based compensation

353

330

199

5,983

0

0

0

-1,553

1,553

1,837

1,224

1,156

1,263

1,287

1,384

1,009

998

1,086

1,142

998

803

745

657

673

435

357

292

194

105

Contingent payment settled in common stock

-

-

-

-

-

-

-

-

89

256

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

45

-

-

7

13

Changes in operating assets and liabilities:
Other current assets and prepaid expenses

2,172

-1,234

1,596

1,610

252

120

-41

-228

-69

-290

-432

241

316

88

-334

496

-18

-487

-577

1,083

-162

-685

191

134

81

140

547

238

216

Accounts payable

-973

-1,380

2,341

-543

-880

1,005

-334

674

-145

76

165

-350

396

-339

240

1

-361

678

-335

-173

111

188

-479

395

-58

-340

23

143

83

Accrued expenses

704

-

6

-213

158

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-468

956

1,609

-1,428

-35

28

20

394

-441

1,978

1,010

1,469

33

1,303

-93

-321

-1,476

-2,022

-1,437

-45

-80

1,755

1,089

588

1,964

27

1,046

946

247

Accrued expenses and other liabilities

-

-

-

-

-

-

-

-

-31

17

17

-11

-17

-20

5

-43

-40

-42

-8

-38

-38

-

-

-

-

-

-

-

-

Net cash used in operating activities

-11,029

-

-

-

-5,317

-

-

-

-13,074

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-10,150

-10,910

-

-7,889

-8,827

-9,956

-9,291

-12,038

-15,117

-13,506

-10,393

-11,190

-9,878

-9,364

-10,135

-8,104

-5,854

-4,555

Cash flows from investing activities:
Purchases of property and equipment

4

25

13

10

7

20

5

-143

150

111

169

131

274

119

272

40

125

48

312

1,306

674

44

320

236

809

307

619

438

120

Purchases of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,999

1,000

Sales of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

5,001

7,000

4,999

Cash distribution in connection with ELAD Assets sale

-

-

-

-

-

-

-

-

-

-

-

-

-

-18

-221

-81

-213

-536

-348

-116

-59

139

221

227

44

218

104

323

-37

Proceeds from sale of equipment

-

-

-

-

-

0

0

0

0

0

0

4

3

0

0

0

2

0

0

0

0

-

-

-

-

-

-

-

0

Net cash used in investing activities

-4

-

-

-

-7

-

-

-

-150

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-127

-271

-

-51

41

90

488

36

-1,190

-615

-183

-541

-463

-853

-525

4,278

4,240

3,916

Cash flows from financing activities:
Proceeds from issuance of common stock in pre-closing financing, net of issuance costs of $61

-

-

-

-

-

-

-

-

-

4

0

0

1

0

0

0

32

241

88

47

139

-

-

-

-

26

25

84

0

Deferred financing costs

-

-

-

-

-

-

-

-

30

-

26

60

0

-

-5

-10

30

-

270

51

0

-

-

-

-

-

-

-

-

Proceeds from public offering of common stock, net of issuance costs of $37

568

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Principal payments on term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance of preferred stock

-

-

-

-

-

-

-

-

-

469

-150

-146

37,825

1,106

2,426

4,498

4,325

-

-

0

0

-

-

-

-

-

-

-

0

Proceeds from stock subscription not yet issued

0

-

0

-20,531

20,531

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

18,167

19,098

0

31,786

2,311

Proceeds from debt, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-19

19

-94

94

-

-

-

-

Net cash provided by financing activities

568

-

-

-

20,531

-

-

-

-30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from early exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-26

-26

279

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-206

37,826

-

2,431

4,508

4,327

32,468

-182

-4

139

33,723

-18

55,140

18,073

17,688

-1,456

31,902

2,311

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-326

492

-1,145

324

-260

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, cash equivalents and restricted cash

-10,791

-1,091

-5,661

8,102

14,947

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Valuation of future purchase rights upon issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

400

0

222

672

Beneficial conversion underlying the senior preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

673

0

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,362

3,048

2,171

2,047

1,115

970

Amortization of deemed dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

4,722

22

-

-

-

-

Stock issuance costs included in liabilities

-

-

-

-

-

-

-

-

-

-

-140

-331

481

-

21

-61

65

-

-31

141

0

-

-

-

-

-

-

-

-

Purchases of property and equipment included in liabilities

-

-

-

-

-

-

-

-

7

-5

-109

43

87

-51

56

36

0

-20

-35

-870

934

271

-288

192

102

15

-208

352

11

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-410

410

-336

336

-254

-241

889

0

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Supplemental disclosure of noncash investing and financing activities:
Leased assets obtained in exchange for operating lease liabilities

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of assets through debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of Series D warrant in connection with Series D redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Conversion of debt for redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Conversion of convertible preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Purchase of property and equipment included in accounts payable

7

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reconciliation of cash, cash equivalents and restricted cash:
Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

-1

0

-1

-3

-8

0

1

0

0

0

-1

0

1

-1

3

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

-13,254

-9,490

-9,762

-10,483

26,645

-8,097

-5,510

-4,278

-5,540

23,662

-12,192

-16,311

-13,981

23,147

-11,749

44,799

7,855

7,028

-5,281

30,287

1,675

Leasehold improvements paid for by landlord

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in stock option early exercise repurchase liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26

26

26

26

26

-

-

-

-

Change in stock option early exercise repurchase liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

23

-

-

-

-

-

-

-

-

-

-

-

-